JIE SHEN

Dr. JIE SHEN


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Frontiers in Chemistry
Verified
Journal Article
Open access
YGYing Gao
Ying Gao
DGDongruo Gao
Dongruo Gao
JSJIE SHEN
JIE SHEN
QWQiwen Wang
Qiwen Wang
Chemotherapy is an important anti-tumor treatment in clinic to date, however, the effectiveness of traditional chemotherapy is limited by its poor selectivity, high systemic toxicity, and multidrug resistance. In recent years, mesoporous silica nanoparticles (MSNs) have become exciting drug delivery systems (DDS) due to their unique advantages, such as easy large-scale production, adjustable uniform pore size, large surface area and pore volumes. While mesoporous silica-based DDS can improve chemotherapy to a certain extent, when used in combination with other cancer therapies MSN based chemotherapy exhibits a synergistic effect, greatly improving therapeutic outcomes. In this review, we discuss the applications of MSN DDS for a diverse range of chemotherapeutic combination anti-tumor therapies, including phototherapy, gene therapy, immunotherapy and other less common modalities. Furthermore, we focus on the characteristics of each nanomaterial and the synergistic advantages of the combination therapies. Lastly, we examine the challenges and future prospects of MSN based chemotherapeutic combination therapies.

5 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
CZChaojie Zhu
Chaojie Zhu
JMJunkai Ma
Junkai Ma
ZJZhiheng Ji
Zhiheng Ji
JSJIE SHEN
JIE SHEN
QWQiwen Wang
Qiwen Wang
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, causing approximately 17.9 million deaths annually, an estimated 31% of all deaths, according to the WHO. CVDs are essentially rooted in atherosclerosis and are clinically classified into coronary heart disease, stroke and peripheral vascular disorders. Current clinical interventions include early diagnosis, the insertion of stents, and long-term preventive therapy. However, clinical diagnostic and therapeutic tools are subject to a number of limitations including, but not limited to, potential toxicity induced by contrast agents and unexpected bleeding caused by anti-platelet drugs. Nanomedicine has achieved great advancements in biomedical area. Among them, cell membrane coated nanoparticles, denoted as CMCNPs, have acquired enormous expectations due to their biomimetic properties. Such membrane coating technology not only helps avoid immune clearance, but also endows nanoparticles with diverse cellular and functional mimicry. In this review, we will describe the superiorities of CMCNPs in treating cardiovascular diseases and their potentials in optimizing current clinical managements.

24 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CZChaojie Zhu
Chaojie Zhu
ZJZhiheng Ji
Zhiheng Ji
JMJunkai Ma
Junkai Ma
ZDZhijie Ding
Zhijie Ding
JSJIE SHEN
JIE SHEN
QWQiwen Wang
Qiwen Wang
Cancer is one of the most devastating and ubiquitous human diseases. Conventional therapies like chemotherapy and radiotherapy are the most widely used cancer treatments. Despite the notable therapeutic improvements that these measures achieve, disappointing therapeutic outcome and cancer reoccurrence commonly following these therapies demonstrate the need for better alternatives. Among them, bacterial therapy has proven to be effective in its intrinsic cancer targeting ability and various therapeutic mechanisms that can be further bolstered by nanotechnology. In this review, we will discuss recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems in cancer treatment. Therapeutic mechanisms of these hybrid nanoformulations are highlighted to provide an up-to-date understanding of this emerging field.

22 June 2018 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
DWDan Wu
Dan Wu
YLYang Li
Yang Li
JSJIE SHEN
JIE SHEN
ZTZaizai Tong
Zaizai Tong
QHQinglian Hu
Qinglian Hu
GYGuocan Yu
Guocan Yu
Based on the host–guest interaction between a CPT-conjugated prodrug amphiphile (CPT-ss-Py) and a water-soluble pillar[5]arene (P5), a GSH-responsive supramolecular chemotherapeutic drug (P5⊃CPT-ss-Py) was fabricated. Through this supramolecular formulation, internalization and anticancer efficacy were greatly increased.

9 December 2020 in Materials Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
DLDahai Liu
Dahai Liu
JDJianshi Du
Jianshi Du
SQShaolong Qi
Shaolong Qi
MLMengyao Li
Mengyao Li
JWJianfeng Wang
Jianfeng Wang
JSJIE SHEN
JIE SHEN
Fluorophores with aggregation-induced emission (AIE) characteristics have attracted more and more attention due to their unparalleled advantages in terms of sensitivity and photostability, and have been extensively utilized for disease diagnosis and therapy. However, it remains challenging to restrict the intramolecular rotation of the AIE luminogens (AIEgens) both in solution and aggregated states. Herein, we utilize host–guest chemistry to achieve this meaningful goal by using a carboxylate-modified pillar[5]arene H as a supramolecular host and an AIEgen containing a tetraphenylethene core G as a guest. The AIE effect of the fluorophore is effectively enhanced upon the formation of an inclusion host–guest complex H⊃G, and the fluorescence of H⊃G is much more intensive than that of free G. Supramolecular nanoparticles (SNPs) with high emission are prepared from H⊃G using a nanoprecipitation method, which can be used as a fluorescent probe for living cell imaging showing superior photostability against laser excitation. Intriguingly, the formed SNPs act as nanocarriers to encapsulate doxorubicin (DOX) to deactivate both the fluorescence of SNPs and DOX caused by the energy transfer relay (ETR) effect, which is mediated by Förster resonance energy transfer and aggregation-caused quenching. The release of loaded DOX after cellular internalization interrupts the ETR effect to light up the silenced fluorescence, thus allowing in situ visualization of drug release. More importantly, the anticancer efficacy of the loaded drug is greatly maintained using this sophisticated supramolecular system, showing promising potential in imaging-guided drug delivery.

15 November 2019 in RSC Advances
Verified
Journal Article
Open access
PDF file
JSJIE SHEN
JIE SHEN
QWQiwen Wang
Qiwen Wang
JFJie Fang
Jie Fang
WSWangxing Shen
Wangxing Shen
DWDan Wu
Dan Wu
Jie YangJie Yang
Jie Yang
To obtain an efficient dual-drug release and enhance therapeutic efficiency for combination chemotherapy, a glutathione (GSH)-responsive therapeutic amphiphilic polyprodrug copolymer (mPEG-b-PCPT) is synthesized to load doxorubicin (DOX) via hydrophobic and π–π stacking interaction. In this nanomedicine system (mPEG-b-PCPT/DOX), the ratio of the two drugs can be easily modulated by changing the loading content of DOX. The in vitro drug release curves and laser confocal images suggested that the release of CPT and DOX is induced through a “release promotes release strategy”: after internalization into tumor cells, the disulfide bonds in the nanomedicine are cleaved by glutathione (GSH) in the cytoplasm and then lead to the release of CPT. Meanwhile, the disassembly of nanomedicine immediately promotes the co-release of DOX. The optimum dose ratio of CPT and DOX is evaluated via the combination index (CI) value using HepG-2 cells. The results of cell apoptosis and cell viability prove the better synergistic efficiency of the nanomedicine than free drugs at the optimum dose ratio of 1. Consequently, this stimuli-responsive synergistic chemotherapy system provides a direction for the fabrication of nanomedicines possessing promising potential in clinical trials.